Maratha Headlines

Chronic Spontaneous Urticaria Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Sanofi, Novartis, Genentech, United BioPharma, Celldex Therapeutics

 Breaking News
  • No posts were found

Chronic Spontaneous Urticaria Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Sanofi, Novartis, Genentech, United BioPharma, Celldex Therapeutics

September 14
05:04 2022
Chronic Spontaneous Urticaria Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Sanofi, Novartis, Genentech, United BioPharma, Celldex Therapeutics
DelveInsight’s “Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Spontaneous Urticaria market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Spontaneous Urticaria pipeline products will significantly revolutionize the Chronic Spontaneous Urticaria market dynamics.  

 

Chronic Spontaneous Urticaria Overview

Chronic spontaneous urticaria (CSU) or Chronic Idiopathic urticaria (CIU) is defined as persistent symptoms of urticaria for 6 weeks or more. It is a distressing skin condition that causes red, swollen, itchy, and sometimes painful hives or “wheals” on the skin. It is associated with autoimmunity in almost half of the cases, but the remaining cases still remain “idiopathic,” and all are considered spontaneous. Therefore, the term chronic spontaneous urticaria (CSU) has been employed to indicate chronic urticaria that is endogenous and is independent of any external physical stimulus, which is conceptually helpful and does not imply knowing or not-knowing the cause.

 

Some of the key facts of the Chronic Spontaneous Urticaria Market Report

  • The Chronic Spontaneous Urticaria market size is anticipated to grow with a significant CAGR during the study period (2019-2032)  
  • The annual prevalence rates of Chronic Spontaneous Urticaria over a 12-year period (2002-2013) were estimated, along with demographic and clinical determinants 
  • As per a study by T. Zuberbier et al., the lifetime prevalence for any subtype of urticaria is approximately 20% 
  • According to the studies by Napolitano et al., the chronic urticaria prevalence in adults is estimated at 0.5% to 5%, while it affects 0.1% to 3% of children 
  • Key Chronic Spontaneous Urticaria Companies: Sanofi, Novartis, Genentech, United BioPharma, Celldex Therapeutics, Taiho Pharmaceutical Co., Ltd., and others
  • Key Chronic Spontaneous Urticaria Therapies: TAS5315, Ligelizumab, Remibrutinib, MTPS9579A, UB-221, CDX-0159, Dupilumab, and others 
  • The Chronic Spontaneous Urticaria epidemiology based on gender analyzed that Chronic Spontaneous Urticaria is more common in females than in male

 

Get a Free sample for the Chronic Spontaneous Urticaria Market Report

 

Key benefits of the Chronic Spontaneous Urticaria Market report:

  1. Chronic Spontaneous Urticaria market report covers a descriptive overview and comprehensive insight of the Chronic Spontaneous Urticaria Epidemiology and Chronic Spontaneous Urticaria market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Chronic Spontaneous Urticaria market report provides insights on the current and emerging therapies.
  3. Chronic Spontaneous Urticaria market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Chronic Spontaneous Urticaria market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Chronic Spontaneous Urticaria market.

 

Discover more about therapies set to grab major Chronic Spontaneous Urticaria market share @ Chronic Spontaneous Urticaria market forecast

 

Chronic Spontaneous Urticaria Epidemiology Segmentation:

The Chronic Spontaneous Urticaria market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Chronic Spontaneous Urticaria
  • Prevalent Cases of Chronic Spontaneous Urticaria by severity
  • Gender-specific Prevalence of Chronic Spontaneous Urticaria
  • Diagnosed Cases of Episodic and Chronic Chronic Spontaneous Urticaria 

 

Chronic Spontaneous Urticaria Market  

The dynamics of the Chronic Spontaneous Urticaria market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The primary principle of Chronic Spontaneous Urticaria treatment is to eliminate symptoms, including pruritus, wheals, and angioedema. H1-antihistamines function as inverse agonists that combine with and stabilize the inactive conformation of the H1-receptor. The treatment plan for chronic urticaria focuses on the treatment of the identifiable cause, avoidance of aggravating factors, and antihistamines trial.”

 

Download the report to understand which factors are driving Chronic Spontaneous Urticaria epidemiology trends @ Chronic Spontaneous Urticaria Epidemiological Insights 

 

Chronic Spontaneous Urticaria Market Drivers

  • Treatment Side Effects with Currently Available Chronic Spontaneous Urticaria Treatment
  • Economic Burden on Patients
  • Increase in Research and Development Activities
  • Increasing Chronic Spontaneous Urticaria Market Size

 

Emerging Chronic Spontaneous Urticaria Therapies and Key Companies

  • TAS5315: Sanofi
  • Ligelizumab: Novartis
  • Remibrutinib: Genentech
  • MTPS9579A: United BioPharma
  • UB-221: Celldex Therapeutics
  • CDX-0159: Taiho Pharmaceutical Co., Ltd.
  • Dupilumab: Novartis

 

Scope of the Chronic Spontaneous Urticaria Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Chronic Spontaneous Urticaria Companies: Sanofi, Novartis, Genentech, United BioPharma, Celldex Therapeutics, Taiho Pharmaceutical Co., Ltd., and others
  • Key Chronic Spontaneous Urticaria Therapies: TAS5315, Ligelizumab, Remibrutinib, MTPS9579A, UB-221, CDX-0159, Dupilumab, and others
  • Therapeutic Assessment: Chronic Spontaneous Urticaria current marketed and Chronic Spontaneous Urticaria emerging therapies
  • Chronic Spontaneous Urticaria Market Dynamics:  Chronic Spontaneous Urticaria market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Chronic Spontaneous Urticaria  Market Access and Reimbursement 

 

Chronic Spontaneous Urticaria Market Barriers

  • Lack of Understanding of Disease Pathology
  • Approaching Patent Cliff

 

Table of Contents 

1. Chronic Spontaneous Urticaria Market Report Introduction

2. Executive Summary for Chronic Spontaneous Urticaria

3. SWOT analysis of Chronic Spontaneous Urticaria

4. Chronic Spontaneous Urticaria Patient Share (%) Overview at a Glance

5. Chronic Spontaneous Urticaria Market Overview at a Glance

6. Chronic Spontaneous Urticaria Disease Background and Overview

7. Chronic Spontaneous Urticaria Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Spontaneous Urticaria 

9. Chronic Spontaneous Urticaria Current Treatment and Medical Practices

10. Chronic Spontaneous Urticaria Unmet Needs

11. Chronic Spontaneous Urticaria Emerging Therapies

12. Chronic Spontaneous Urticaria Market Outlook

13. Country-Wise Chronic Spontaneous Urticaria Market Analysis (2019–2032)

14. Chronic Spontaneous Urticaria Market Access and Reimbursement of Therapies

15. Chronic Spontaneous Urticaria Market drivers

16. Chronic Spontaneous Urticaria Market barriers

17.  Chronic Spontaneous Urticaria Appendix

18. Chronic Spontaneous Urticaria Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Chronic Spontaneous Urticaria treatment, visit @ Chronic Spontaneous Urticaria Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/